文献速递新发突发、热带与寄生虫病

单克隆抗体干预疟疾的应用前景:一项叙述性综述

The promise of monoclonal antibody interventions in malaria: a narrative review.
PubMed 文献 · Clin Microbiol Infect · 2026-08-22

该叙述性综述通过检索PubMed至2026年6月的文献,总结了恶性疟原虫免疫机制及单克隆抗体干预的临床转化证据。CIS43LS、L9LS、MAM01和TB31F等单克隆抗体在受控人类疟疾感染和现场试验中显示出良好安全性、长血清半衰期及高保护水平。长效力单克隆抗体有望补充现有疟疾控制策略,为高风险人群提供快速、高效且持久的保护。

要点

  • 单克隆抗体CIS43LS、L9LS、MAM01和TB31F在试验中显示良好安全性、长半衰期和高保护力。
  • 长效力单克隆抗体可补充现有疟疾控制策略,尤其适用于幼儿、孕妇和季节性传播地区人群。
  • 优化抗体效力、持久性和递送平台,并确定可靠的保护免疫相关指标,是未来整合的关键。

核心结论

  • 单克隆抗体是疟疾预防的有前景工具,长效力单克隆抗体可补充现有控制策略。

研究设计与样本

  • 叙述性综述,检索PubMed至2026年6月,纳入免疫学原始研究、转化研究、临床试验和综述文章。

主要发现

  • CIS43LS、L9LS、MAM01和TB31F等单克隆抗体在受控人类疟疾感染和现场试验中表现出良好安全性、长血清半衰期和高水平保护。
  • 保护性免疫涉及功能性抗体反应、细胞介导免疫、细胞因子调节和免疫记忆等机制与生物标志物。

临床怎么用

  • 长效力单克隆抗体可考虑用于幼儿、孕妇和季节性传播地区等感染风险最高人群的补充预防。
  • 未来需优化抗体效力、持久性和递送平台,并确定可靠的保护免疫相关指标以整合入疟疾控制规划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malaria remains a leading cause of morbidity and mortality globally, particularly in sub-Saharan Africa. Despite repeated exposure and vaccine deployment, sterile immunity against malaria rarely develops. Advances in malaria immunology over the past decades have revealed complex host-parasite interactions that shape clinical outcomes and inform new therapeutic strategies. OBJECTIVES: This narrative review aims to highlight the emerging role of monoclonal antibody interventions for malaria prevention. SOURCES: Relevant articles were identified through a search of PubMed up to June 2026. Search terms included 'malaria immunology', 'Plasmodium falciparum', 'monoclonal antibodies', and 'immune correlates'. Additional references were identified from the bibliographies of relevant publications. Articles were selected based on relevance to clinical translation. CONTENT: This review synthesizes evidence from primary immunology studies, translational research, clinical trials, and review articles to provide an updated overview of P. falciparum immunity and monoclonal antibody-based interventions. It highlights key immunological mechanisms and biomarkers associated with protective immunity, including functional antibody responses, cell-mediated immunity, cytokine regulation, and immune memory. It further summarizes the clinical development of leading monoclonal antibodies, including CIS43LS, L9LS, MAM01, and TB31F, which have demonstrated favourable safety profiles, prolonged serum half-lives, and high levels of protection against P. falciparum infection in controlled human malaria infection and field trials. The findings support monoclonal antibodies as promising tools for malaria prevention. IMPLICATIONS: Current evidence indicates that long-acting monoclonal antibodies have the potential to complement existing malaria control strategies by providing rapid, highly effective, and durable protection, particularly for populations at greatest risk of infection, including young children, pregnant women, and individuals in seasonal transmission settings. Continued optimization of antibody potency, durability, and delivery platforms, together with the identification of robust immune correlates of protection, will be critical for integrating monoclonal antibodies into future malaria control programs.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Rashid MA, Tumbo AM, Hassan OZ, et al. The promise of monoclonal antibody interventions in malaria: a narrative review. Clin Microbiol Infect. 2026. PMID: 42632421. doi:10.1016/j.cmi.2026.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。